Blue Earth Diagnostics, a Bracco Company, Appoints Marco Campione as Chief Executive Officer to Lead Next Phase of Company Growth

• Mr. Campione has over 25 years of global experience in the successful development and commercialization of diagnostic imaging and radiopharmaceuticals.
• Blue Earth Diagnostics Co-Founder and Former CEO David Gauden, D.Phil., Named Full-Time CEO of Sister Company Blue Earth Therapeutics
• Executive Appointments to Optimize Growth and Industry Leadership for Both Bracco Companies

MONROE TOWNSHIP, N.J. AND OXFORD, ENGLAND–(BUSINESS WIRE)– Bracco AND Blue Earth Diagnostics Sp. z o. o.Bracco, a company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced the appointment of Marco Campione as its new Chief Executive Officer (CEO), reporting to Bracco Imaging CEO Fulvio Renoldi Bracco. Mr. Campione also joins the board of Blue Earth Diagnostics Ltd and will serve as Vice Chairman of the Board of Blue Earth Diagnostics Inc. Dr. David Gauden, co-founder of Blue Earth Diagnostics and with the company since 2014, is taking on the role of full-time CEO of Bracco’s subsidiary Blue Earth Therapeutics. The changes reflect a carefully planned strategy to drive continued growth, development and opportunity for both companies and Bracco.

This press release contains multimedia. View the full release here: https://www.businesswire.com/news/home/20240708534807/en/

Marco Campione, CEO of Blue Earth Diagnostics, a Bracco company (photo: Business Wire)

“I congratulate Marco Campione on his appointment as CEO and we look forward to benefiting from his strategic, operational and broad business expertise as we expand our global leadership in the diagnostic radiopharmaceuticals industry,” said Fulvio Renoldi Bracco, CEO of Bracco Imaging. “Marco joins Bracco Group at a pivotal moment in our evolution as the company matures, broadens its horizons worldwide and expands its commercial presence.”

Mr. Renoldi continued, “I would also like to take this opportunity to recognize David Gauden’s contributions to the success of Blue Earth Diagnostics and wish him every success in leading Blue Earth Therapeutics as full-time Chief Executive Officer.”

“I am excited and honored to assume the role of CEO of Blue Earth Diagnostics,” said Mr. Campione. “The company is a recognized leader in the nuclear medicine and oncology communities with a strong reputation for successful innovation, execution and dedicated service to patient health. I look forward to leveraging my experience to expand the availability of the company’s PET imaging products for prostate cancer, advancing its development programs in neuro-oncology PET and solid tumors, and exploring additional opportunities and collaborations.”

Marco Campione has more than 25 years of experience with GE HealthCare, where he most recently served as Executive Director and Global Head of Contrast Media, General Manager of the Diagnostics Pharmaceutical Business Unit in North America, and President of GE HealthCare Inc.

About Blue Earth Diagnostics
Blue Earth Diagnostics, a subsidiary of Bracco Imaging SpA, is a growing international molecular imaging company committed to delivering innovative, well-differentiated diagnostic solutions that inform patient care. Founded in 2014, the company’s success is based on management experience and a proven track record of rapid development and commercialization of radiopharmaceuticals for positron emission tomography (PET). Blue Earth Diagnostics’ expanding oncology portfolio spans a range of disease states, including prostate cancer and neuro-oncology. Blue Earth Diagnostics is committed to the timely development and commercialization of precision radiopharmaceuticals for potential imaging and therapeutic applications. For more information, visit www.blueearthdiagnostics.com.

About Bracco Imaging
Bracco Imaging SpA, part of Bracco Group, is a leading global provider of diagnostic imaging services. Headquartered in Milan, Italy, Bracco Imaging develops, manufactures and markets diagnostic imaging agents and solutions. It offers a portfolio of products and solutions for all key diagnostic imaging modalities: X-ray imaging (including computed tomography-CT, interventional radiology and cardiac catheterization), magnetic resonance imaging (MRI), contrast-enhanced ultrasound (CEUS) and nuclear medicine using radioactive tracers and new PET imaging agents to inform clinical management and guide the care of oncology patients in areas of unmet medical need. Our constantly evolving portfolio is complemented by a range of medical devices, advanced delivery systems and dose management software. In 2019, Bracco Imaging further enhanced its product portfolio by expanding its range of nuclear imaging solutions for oncology in the urology segment and other specialties with the acquisition of Blue Earth Diagnostics. In 2021, Bracco Imaging founded Blue Earth Therapeutics as a distinct, cutting-edge biotechnology vehicle for the development of radiopharmaceutical therapies. Visit: www.braccoimaging.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240708534807/en/